Tubidy
    Weighing the cost versus benefit of PCSK9-targeted therapy | Professor Lluis Masana

    Weighing the cost versus benefit of PCSK9-targeted therapy | Professor Lluis Masana

    02:27 |
    Download MP3

    Related Videos

    PCSK9 Forum Invitation | Professor John Chapman 3:11

    PCSK9 Forum Invitation | Professor John Chapman

    PCSK9 inhibitors: How do we weigh up the benefit versus cost of treatment 6:46

    PCSK9 inhibitors: How do we weigh up the benefit versus cost of treatment

    PCSK9 Forum Invitation | Professor John Chapman 1:21

    PCSK9 Forum Invitation | Professor John Chapman

    PCSK9 Forum News Editor Dr Peter Lansberg discusses ODYSSEY ESCAPE 7:12

    PCSK9 Forum News Editor Dr Peter Lansberg discusses ODYSSEY ESCAPE

    How will PCSK9 inhibitors be used in practice? 3:34

    How will PCSK9 inhibitors be used in practice?

    The Cholesterol Wars: Identifying Patients Who Would Most Benefit from PCSK9 Inhibitors (Part 1) 58:08

    The Cholesterol Wars: Identifying Patients Who Would Most Benefit from PCSK9 Inhibitors (Part 1)

    Looking ahead with PCSK9 Education & Research Forum | Professor Henry Ginsberg 1:43

    Looking ahead with PCSK9 Education & Research Forum | Professor Henry Ginsberg

    The PCSK9 Decade | Professor John Chapman 2:04

    The PCSK9 Decade | Professor John Chapman

    Prof Raul Santos: Do PCSK9 inhibitors have adverse effects on neurocognition 1:54

    Prof Raul Santos: Do PCSK9 inhibitors have adverse effects on neurocognition

    PCSK9 and Lp(a), a novel approach to a CV risk factor | Professor Henry Ginsberg 1:17

    PCSK9 and Lp(a), a novel approach to a CV risk factor | Professor Henry Ginsberg

    New era in cholesterol-lowering? PCSK9 inhibitors soon available? 13:18

    New era in cholesterol-lowering? PCSK9 inhibitors soon available?

    Could PCSK9 inhibitors be used in children with FH 2:05

    Could PCSK9 inhibitors be used in children with FH

    What are the gaps in knowledge about the PCSK9 inhibitors | Dr Evan Stein 1:40

    What are the gaps in knowledge about the PCSK9 inhibitors | Dr Evan Stein

    Does PCSK9 have effects beyond the liver? | Professor Bertrand Cariou 7:20

    Does PCSK9 have effects beyond the liver? | Professor Bertrand Cariou

    Is lipoprotein(a) a cause of clinical familial hypercholesterolaemia? 2:36

    Is lipoprotein(a) a cause of clinical familial hypercholesterolaemia?

    2022 FORUM Sir Colin Dollery Lecture with Prof Dan Roden 44:18

    2022 FORUM Sir Colin Dollery Lecture with Prof Dan Roden

    Prof Kausik Ray gives an analysis of the PCSK9 inhibitor outcomes studies 3:55

    Prof Kausik Ray gives an analysis of the PCSK9 inhibitor outcomes studies

    Will PCSK9 monoclonal antibodies replace other lipid lowering treatment | Professor Frederick Raal 1:38

    Will PCSK9 monoclonal antibodies replace other lipid lowering treatment | Professor Frederick Raal

    Weighing the cost versus benefit of PCSK9-targeted therapy | Professor Lluis Masana 2:28

    Weighing the cost versus benefit of PCSK9-targeted therapy | Professor Lluis Masana

    How will FOURIER impact clinical practice, including treatment access? 3:34

    How will FOURIER impact clinical practice, including treatment access?